Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25242026 | 1.00 | FOLH1 (0.37) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL19732156 | 0.99 | FOLH1 (0.37) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL31681443 | 0.94 | SIRT1 (0.37) | SIRT1SIRT2 | |
| SCHEMBL25245450 | 0.93 | FOLH1 (0.35) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL27190126 | 0.90 | HDAC8 (0.34) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL27189832 | 0.90 | HDAC8 (0.34) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL26066853 | 0.90 | HDAC8 (0.39) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL26066857 | 0.90 | HDAC8 (0.39) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL21118854 | 0.86 | FOLH1 (0.36) | FOLH1HDAC1HDAC7 | |
| SCHEMBL22388632 | 0.83 | FOLH1 (0.37) | FOLH1HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325690-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | PINOTBIO, INC. (KR) | 2025-10-23 | — | — | US | disclosed |
| US-20250161474-A1 | ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-05-22 | — | — | US | disclosed |
| WO-2023249473-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | 주식회사 피노바이오 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023214849-A1 | CONJUGATE OF DDX5 PROTEIN-BINDING CAMPTOTHECIN-BASED DRUG LINKED TO ACID-SENSITIVE LINKER AND IMMUNOCONJUGATE USING SAME | 주식회사 피노바이오 | 2023-11-09 | — | — | WO | disclosed |
| US-20230270867-A1 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | PINOTBIO, INC. (KR) | 2023-08-31 | — | — | US | disclosed |
| EP-4183418-A1 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | Pinotbio, Inc. (KR) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270867-A1 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | SLC46A1, SLC47A1, FOLR1 | FOLH1 10/4885HDAC8 1121/4885HDAC1 3656/4885 |
| US-20250325690-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | DDX1, DDX18, DDX24 | FOLH1 263/4885HDAC8 907/4885HDAC1 2621/4885 |
| US-20250161474-A1 | ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF | MET, EGFR, ERBB2 | FOLH1 155/4885HDAC8 4376/4885HDAC1 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.